In patients with KRAS-mutant NSCLC who were treated with ICI monotherapies or ICI combination therapies, the response rate was remarkably higher in the group with TP53 co-mutation compared to the group with STK11 co-mutation (28). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.